1
|
Hoving JJA, Harford-Wright E, Wingfield-Digby P, Cattin AL, Campana M, Power A, Morgan T, Torchiaro E, Quereda V, Lloyd AC. N-cadherin directs the collective Schwann cell migration required for nerve regeneration through Slit2/3-mediated contact inhibition of locomotion. eLife 2024; 13:e88872. [PMID: 38591541 PMCID: PMC11052573 DOI: 10.7554/elife.88872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Accepted: 03/27/2024] [Indexed: 04/10/2024] Open
Abstract
Collective cell migration is fundamental for the development of organisms and in the adult for tissue regeneration and in pathological conditions such as cancer. Migration as a coherent group requires the maintenance of cell-cell interactions, while contact inhibition of locomotion (CIL), a local repulsive force, can propel the group forward. Here we show that the cell-cell interaction molecule, N-cadherin, regulates both adhesion and repulsion processes during Schwann cell (SC) collective migration, which is required for peripheral nerve regeneration. However, distinct from its role in cell-cell adhesion, the repulsion process is independent of N-cadherin trans-homodimerisation and the associated adherens junction complex. Rather, the extracellular domain of N-cadherin is required to present the repulsive Slit2/Slit3 signal at the cell surface. Inhibiting Slit2/Slit3 signalling inhibits CIL and subsequently collective SC migration, resulting in adherent, nonmigratory cell clusters. Moreover, analysis of ex vivo explants from mice following sciatic nerve injury showed that inhibition of Slit2 decreased SC collective migration and increased clustering of SCs within the nerve bridge. These findings provide insight into how opposing signals can mediate collective cell migration and how CIL pathways are promising targets for inhibiting pathological cell migration.
Collapse
Affiliation(s)
- Julian JA Hoving
- UCL Laboratory for Molecular Cell Biology and the UCL Cancer Institute, University College LondonLondonUnited Kingdom
| | - Elizabeth Harford-Wright
- UCL Laboratory for Molecular Cell Biology and the UCL Cancer Institute, University College LondonLondonUnited Kingdom
| | - Patrick Wingfield-Digby
- UCL Laboratory for Molecular Cell Biology and the UCL Cancer Institute, University College LondonLondonUnited Kingdom
| | - Anne-Laure Cattin
- UCL Laboratory for Molecular Cell Biology and the UCL Cancer Institute, University College LondonLondonUnited Kingdom
| | - Mariana Campana
- UCL Laboratory for Molecular Cell Biology and the UCL Cancer Institute, University College LondonLondonUnited Kingdom
| | - Alex Power
- UCL Laboratory for Molecular Cell Biology and the UCL Cancer Institute, University College LondonLondonUnited Kingdom
| | - Toby Morgan
- UCL Laboratory for Molecular Cell Biology and the UCL Cancer Institute, University College LondonLondonUnited Kingdom
| | - Erica Torchiaro
- UCL Laboratory for Molecular Cell Biology and the UCL Cancer Institute, University College LondonLondonUnited Kingdom
| | - Victor Quereda
- UCL Laboratory for Molecular Cell Biology and the UCL Cancer Institute, University College LondonLondonUnited Kingdom
| | - Alison C Lloyd
- UCL Laboratory for Molecular Cell Biology and the UCL Cancer Institute, University College LondonLondonUnited Kingdom
| |
Collapse
|
2
|
Torchiaro E, Petti C, Arena S, Sassi F, Migliardi G, Mellano A, Porporato R, Basiricò M, Gammaitoni L, Berrino E, Montone M, Corti G, Crisafulli G, Marchiò C, Bardelli A, Medico E. Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient. Front Oncol 2023; 13:1130852. [PMID: 36816936 PMCID: PMC9932521 DOI: 10.3389/fonc.2023.1130852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Accepted: 01/12/2023] [Indexed: 02/05/2023] Open
Abstract
High-grade mucinous colorectal cancer (HGM CRC) is particularly aggressive, prone to metastasis and treatment resistance, frequently accompanied by "signet ring" cancer cells. A sizeable fraction of HGM CRCs (20-40%) arises in the context of the Lynch Syndrome, an autosomal hereditary syndrome that predisposes to microsatellite instable (MSI) CRC. Development of patient-derived preclinical models for this challenging subtype of colorectal cancer represents an unmet need in oncology. We describe here successful propagation of preclinical models from a case of early-onset, MSI-positive metastatic colorectal cancer in a male Lynch syndrome patient, refractory to standard care (FOLFOX6, FOLFIRI-Panitumumab) and, surprisingly, also to immunotherapy. Surgical material from a debulking operation was implanted in NOD/SCID mice, successfully yielding one patient-derived xenograft (PDX). PDX explants were subsequently used to generate 2D and 3D cell cultures. Histologically, all models resembled the tumor of origin, displaying a high-grade mucinous phenotype with signet ring cells. For preclinical exploration of alternative treatments, in light of recent findings, we considered inhibition of the proteasome by bortezomib and of the related NEDD8 pathway by pevonedistat. Indeed, sensitivity to bortezomib was observed in mucinous adenocarcinoma of the lung, and we previously found that HGM CRC is preferentially sensitive to pevonedistat in models with low or absent expression of cadherin 17 (CDH17), a differentiation marker. We therefore performed IHC on the tumor and models, and observed no CDH17 expression, suggesting sensitivity to pevonedistat. Both bortezomib and pevonedistat showed strong activity on 2D cells at 72 hours and on 3D organoids at 7 days, thus providing valid options for in vivo testing. Accordingly, three PDX cohorts were treated for four weeks, respectively with vehicle, bortezomib and pevonedistat. Both drugs significantly reduced tumor growth, as compared to the vehicle group. Interestingly, while bortezomib was more effective in vitro, pevonedistat was more effective in vivo. Drug efficacy was further substantiated by a reduction of cellularity and of Ki67-positive cells in the treated tumors. These results highlight proteasome and NEDD8 inhibition as potentially effective therapeutic approaches against Lynch syndrome-associated HGM CRC, also when the disease is refractory to all available treatment options.
Collapse
Affiliation(s)
- Erica Torchiaro
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy
| | - Consalvo Petti
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy
| | - Sabrina Arena
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy.,Department of Oncology, University of Torino, Candiolo, Italy
| | - Francesco Sassi
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy
| | - Giorgia Migliardi
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy
| | - Alfredo Mellano
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy
| | - Roberta Porporato
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy
| | - Marco Basiricò
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy
| | - Loretta Gammaitoni
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy
| | - Enrico Berrino
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy.,Department of Medical Sciences, University of Turin, Torino, Italy
| | - Monica Montone
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy
| | - Giorgio Corti
- Department of Oncology, University of Torino, Candiolo, Italy
| | | | - Caterina Marchiò
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy.,Department of Medical Sciences, University of Turin, Torino, Italy
| | - Alberto Bardelli
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy.,Department of Oncology, University of Torino, Candiolo, Italy
| | - Enzo Medico
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy.,Department of Oncology, University of Torino, Candiolo, Italy
| |
Collapse
|
3
|
Bianchi F, Dama E, Di Nicolantonio F, Baldassarre G, Guerriero I, Torchiaro E, Bruno A, Blandino G, Allavena P, Chiarugi P, Sozzi G, D'Incalci M, Normanno N. COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC). ESMO Open 2021; 6:100165. [PMID: 34052554 PMCID: PMC8176317 DOI: 10.1016/j.esmoop.2021.100165] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Revised: 05/05/2021] [Accepted: 05/05/2021] [Indexed: 11/17/2022] Open
Abstract
Background Italy was among the first countries hit by the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The application of strict lockdown measures disproportionately affected both cancer patient care as well as basic and translational cancer research. Materials and methods The Italian Cancer Society (SIC) conducted a survey on the effect of lockdown on laboratories involved in cancer research in Italy. The survey was completed by 570 researchers at different stages of their career, working in cancer centers, research institutes and universities from 19 Italian regions. Results During the lockdown period, the impact of the COVID-19 pandemic emergency on face-to-face research activities was high, with a complete (47.7%) or partial (36.1%) shutdown of the laboratories. In the post-lockdown period, research activities were resumed in most of the respondents’ institutions (80.4%), though with some restrictions (77.2%). COVID-19 testing was offered to research personnel only in ~50% of research institutions. Overall, the response to the pandemic was fragmented as in many cases institutions adopted different strategies often aimed at limiting possible infections without a clearly defined contingency plan. Nevertheless, research was able to provide the first answers and possible ways out of the pandemic, also with the contribution of many cancer researchers that sacrificed their research programs to help overcome the pandemic by offering their knowledge and technologies. Conclusions Given the current persistence of an emergency situation in many European countries, a more adequate organization of research centers will be urgent and necessary to ensure the continuity of laboratory activities in a safe environment. The SIC conducted a survey on the effect of COVID-19 lockdown on cancer research laboratories in Italy. The impact of the lockdown on research activities was high, with complete or partial shutdown of >80% of the laboratories. Response to the pandemic was fragmented with different strategies adopted without a clearly defined contingency plan. An adequate organization of research centers is urgently needed to ensure laboratory activities in a safe environment.
Collapse
Affiliation(s)
- F Bianchi
- Fondazione IRCCS Casa Sollievo della Sofferenza, Cancer Biomarkers Unit, San Giovanni Rotondo, Italy
| | - E Dama
- Fondazione IRCCS Casa Sollievo della Sofferenza, Cancer Biomarkers Unit, San Giovanni Rotondo, Italy
| | - F Di Nicolantonio
- Department of Oncology, University of Torino, Candiolo, Turin, Italy; Candiolo Cancer Institute, Candiolo, Turin, Italy
| | - G Baldassarre
- Molecular Oncology Unit Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy
| | - I Guerriero
- Biogem, Institute for Genetic Research 'G. Salvatore', Ariano Irpino, Italy
| | - E Torchiaro
- Candiolo Cancer Institute, Candiolo, Turin, Italy
| | - A Bruno
- Laboratory of Immunology, Unit of Molecular Pathology, Immunology and Biochemistry, IRCCS MultiMedica, Milan, Italy
| | - G Blandino
- Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - P Allavena
- Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy
| | - P Chiarugi
- Department of Experimental and Clinical Biomedical Sciences, School of Medicine, University of Florence, Florence, Italy
| | - G Sozzi
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | - M D'Incalci
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - N Normanno
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy.
| |
Collapse
|
4
|
Invrea F, Rovito R, Torchiaro E, Petti C, Isella C, Medico E. Patient-derived xenografts (PDXs) as model systems for human cancer. Curr Opin Biotechnol 2020; 63:151-156. [PMID: 32070860 DOI: 10.1016/j.copbio.2020.01.003] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2020] [Accepted: 01/08/2020] [Indexed: 12/13/2022]
Abstract
Patient-derived xenografts (PDXs) are obtained by transplanting fragments of a patient's tumour into immunodeficient mice. Growth and propagation of PDXs allows correlating therapeutic response in vivo with extensive, multi-dimensional molecular annotation, leading to identification of predictive biomarkers. PDXs are increasingly recognised as clinically relevant models of cancer for several reasons, of which the main is the possibility of studying the behaviour of cancer cells in a natural microenvironment, where they interact with stromal components accrued from the mouse host. PDXs maintain close similarities with the tumour of origin, in terms of tissue architecture, molecular features and response to treatments. Indeed, preclinical trials in PDXs have been shown to match and also anticipate data obtained in patients. Exploration of more complex processes like metastatic evolution and antitumour immune responses is actively pursued with PDXs, as new generations of host models emerge on the horizon.
Collapse
Affiliation(s)
- Federica Invrea
- Candiolo Cancer Institute, FPO-IRCCS, strada Prov. 142, km 3,95, 10060 Candiolo (TO), Italy
| | - Roberta Rovito
- Candiolo Cancer Institute, FPO-IRCCS, strada Prov. 142, km 3,95, 10060 Candiolo (TO), Italy
| | - Erica Torchiaro
- Candiolo Cancer Institute, FPO-IRCCS, strada Prov. 142, km 3,95, 10060 Candiolo (TO), Italy
| | - Consalvo Petti
- Candiolo Cancer Institute, FPO-IRCCS, strada Prov. 142, km 3,95, 10060 Candiolo (TO), Italy
| | - Claudio Isella
- Candiolo Cancer Institute, FPO-IRCCS, strada Prov. 142, km 3,95, 10060 Candiolo (TO), Italy; University of Torino, Department of Oncology, strada Prov. 142, km 3,95, 10060 Candiolo (TO), Italy
| | - Enzo Medico
- Candiolo Cancer Institute, FPO-IRCCS, strada Prov. 142, km 3,95, 10060 Candiolo (TO), Italy; University of Torino, Department of Oncology, strada Prov. 142, km 3,95, 10060 Candiolo (TO), Italy.
| |
Collapse
|
5
|
Torchiaro E, Petti C, Isella C, Medico E. Abstract 4737: Case report: Preclinical testing of NEDD8 and proteasome inhibitors for a treatment-refractory, metastatic high-grade mucinous colorectal cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-4737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Colorectal cancer (CRC) is the third leading cause of death in the world. CRC shows variable phenotypic make-ups; among them, a particularly aggressive histological subtype is the “high grade mucinous” (HGM) adenocarcinoma, highly mucinous, prone to metastasis and typically refractory to treatments. In some cases, HGM is accompanied by a peculiar “signet ring” phenotype of cancer cells. Early stage diagnosis of signet ring HGM is rare, since clinical symptoms tend to occur late and most cases are usually detected at an advanced stage, with a poor overall survival. We previously demonstrated that a transcriptional signature of HGM displays negative prognosis and sensitivity to the NEDD-8 inhibitor pevonedistat, suggesting the involvement of neddylation- and ubiquitination-based mechanisms in these cases (Picco et al., JNCI 2017 djw209). To assess the clinical potential of colorectal cancer HGM identification and targeting by pevonedistat or other inhibitor of proteasome pathway, we recently propagated cells and PDXs from a case of early onset, metastatic CRC in a Lynch syndrome patient, refractory to standard care (FOLFOX6, FOLFIRI-Panitumumab) and, surprisingly, also to nivolumab. The tumor was highly mucinous, with signet ring undifferentiated cells. Mutational analysis on tumor tissue from the first surgery highlighted PIK3CA H1047R mutation and no mutations in KRAS, NRAS or BRAF. Surprisingly, exome analysis on two lesions from a subsequent surgery displayed a different scenario: KRAS G13D but not PIK3CA mutation. Probably these discording results suggest a strong tumor heterogeneity and evolution. Considering the failure of all previous therapies, the lack of actionable genetic alterations and the peculiarity of the phenotypic features, patient-derived models (organoids and 2D cell cultures) were derived from the two latter lesions and tested for sensitivity to the NEDD8 pathway inhibitor pevonedistat and the proteasome inhibitors bortezomib and carfilzomib. Interestingly, all models showed a strong sensitivity to both drugs, in particular to bortezomib. This is an example of a rare case of high-grade mucinous colorectal cancer where the integration of several approaches proves useful to identify possible therapeutic strategies for a patient without further standard treatment options.
Citation Format: Erica Torchiaro, Consalvo Petti, Claudio Isella, Enzo Medico. Case report: Preclinical testing of NEDD8 and proteasome inhibitors for a treatment-refractory, metastatic high-grade mucinous colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4737.
Collapse
Affiliation(s)
| | | | | | - Enzo Medico
- 2Candiolo Cancer Institute and University of Torino, Candiolo, Italy
| |
Collapse
|
6
|
Torchiaro E, Petti C, Isella C, Corti G, Montone M, Mussolin B, Bardelli A, Medico E. Preclinical testing of NEDD8 and proteasome inhbitors for a treatment-refractory, metastatic high-grade mucinous colorectal cancer patient. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy047.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Picco G, Petti C, Centonze A, Torchiaro E, Crisafulli G, Novara L, Acquaviva A, Bardelli A, Medico E. Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions. EMBO Mol Med 2017; 9:293-303. [PMID: 28100566 PMCID: PMC5331210 DOI: 10.15252/emmm.201606773] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
In colorectal cancer (CRC), WNT pathway activation by genetic rearrangements of RSPO3 is emerging as a promising target. However, its low prevalence severely limits availability of preclinical models for in-depth characterization. Using a pipeline designed to suppress stroma-derived signal, we find that RSPO3 "outlier" expression in CRC samples highlights translocation and fusion transcript expression. Outlier search in 151 CRC cell lines identified VACO6 and SNU1411 cells as carriers of, respectively, a canonical PTPRK(e1)-RSPO3(e2) fusion and a novel PTPRK(e13)-RSPO3(e2) fusion. Both lines displayed marked in vitro and in vivo sensitivity to WNT blockade by the porcupine inhibitor LGK974, associated with transcriptional and morphological evidence of WNT pathway suppression. Long-term treatment of VACO6 cells with LGK974 led to the emergence of a resistant population carrying two frameshift deletions of the WNT pathway inhibitor AXIN1, with consequent protein loss. Suppression of AXIN1 in parental VACO6 cells by RNA interference conferred marked resistance to LGK974. These results provide the first mechanism of secondary resistance to WNT pathway inhibition.
Collapse
Affiliation(s)
- Gabriele Picco
- Candiolo Cancer Institute - FPO IRCCS, Candiolo, Torino, Italy.,Department of Oncology, University of Torino, Candiolo, Torino, Italy
| | - Consalvo Petti
- Candiolo Cancer Institute - FPO IRCCS, Candiolo, Torino, Italy.,Department of Oncology, University of Torino, Candiolo, Torino, Italy
| | - Alessia Centonze
- Department of Oncology, University of Torino, Candiolo, Torino, Italy
| | - Erica Torchiaro
- Candiolo Cancer Institute - FPO IRCCS, Candiolo, Torino, Italy.,Istituto Nazionale Biostrutture e Biosistemi - Consorzio Interuniversitario, Roma, Italy
| | | | - Luca Novara
- Candiolo Cancer Institute - FPO IRCCS, Candiolo, Torino, Italy
| | - Andrea Acquaviva
- Department of Computer and Control Engineering, Politecnico di Torino, Turin, Italy
| | - Alberto Bardelli
- Candiolo Cancer Institute - FPO IRCCS, Candiolo, Torino, Italy.,Department of Oncology, University of Torino, Candiolo, Torino, Italy
| | - Enzo Medico
- Candiolo Cancer Institute - FPO IRCCS, Candiolo, Torino, Italy .,Department of Oncology, University of Torino, Candiolo, Torino, Italy
| |
Collapse
|
8
|
Picco G, Petti C, Centonze A, Torchiaro E, Bardelli A, Medico E. Abstract 3151: Loss of Axin1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-3151] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
In colorectal cancer (CRC), WNT pathway activation by genetic rearrangements of RSPO3 is emerging as a promising target. However, its low prevalence severely limits availability of preclinical models for in-depth characterization. Using a pipeline designed to suppress stroma-derived signal, we find that RSPO3 “outlier” expression in CRC samples highlights translocation and fusion transcript expression. Outlier search in 151 CRC cell lines identified VACO6 and SNU1411cells as carriers of, respectively, a canonical PTPRK(e1)-RSPO3(e2) fusion and a novel PTPRK(e13)-RSPO3(e2) fusion. Both lines displayed marked in vitro and in vivo sensitivity to WNT blockade by the porcupine inhibitor LGK974, associated with transcriptional and morphological evidences of WNT pathway suppression. Long-term treatment of VACO6 cells with LGK974 led to the emergence of a resistant population carrying two frameshift deletions of the WNT pathway inhibitor AXIN1, with consequent protein loss. Suppression of AXIN1 in parental VACO6 cells by RNA interference conferred marked resistance to LGK974. These results provide the first mechanism of secondary resistance to WNT pathway inhibition.
Citation Format: Gabriele Picco, Consalvo Petti, Alessia Centonze, Erica Torchiaro, Alberto Bardelli, Enzo Medico. Loss of Axin1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3151. doi:10.1158/1538-7445.AM2017-3151
Collapse
Affiliation(s)
- Gabriele Picco
- 1University of Torino, Candiolo Cancer Institute, Candiolo, Italy
| | | | - Alessia Centonze
- 1University of Torino, Candiolo Cancer Institute, Candiolo, Italy
| | | | - Alberto Bardelli
- 1University of Torino, Candiolo Cancer Institute, Candiolo, Italy
| | - Enzo Medico
- 1University of Torino, Candiolo Cancer Institute, Candiolo, Italy
| |
Collapse
|
9
|
Torchiaro E, Lorenzato A, Olivero M, Valdembri D, Gagliardi PA, Gai M, Erriquez J, Serini G, Di Renzo MF. Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism. Oncotarget 2016; 7:712-28. [PMID: 26625210 PMCID: PMC4808028 DOI: 10.18632/oncotarget.6412] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 11/15/2015] [Indexed: 12/13/2022] Open
Abstract
The molecular mechanisms orchestrating peritoneal and hematogenous metastases of ovarian cancer cells are assumed to be distinct. We studied the p90RSK family of serine/threonine kinases that lie downstream the RAS-ERK/MAPK pathway and modulate a variety of cellular processes including cell proliferation, survival, motility and invasiveness. We found the RSK1 and RSK2 isoforms expressed in a number of human ovarian cancer cell lines, where they played redundant roles in sustaining in vitro motility and invasiveness. In vivo, silencing of both RSK1 and RSK2 almost abrogated short-term and long-term metastatic engraftment of ovarian cancer cells in the peritoneum. In addition, RSK1/RSK2 silenced cells failed to colonize the lungs after intravenous injection and to form hematogenous metastasis from subcutaneous xenografts. RSK1/RSK2 suppression resulted in lessened ovarian cancer cell spreading on endogenous fibronectin (FN). Mechanistically, RSK1/RSK2 knockdown diminished FN transcription, α5β1 integrin activation and TGF-β1 translation. Reduced endogenous FN deposition and TGF-β1 secretion depended on the lack of activating phosphorylation of the transcription/translation factor YB-1 by p90RSK. Altogether data show how p90RSK activates a self-reinforcing cell autonomous pro-adhesive circuit necessary for metastatic seeding of ovarian cancer cells. Thus, p90RSK inhibitors might hinder both the hematogenous and the peritoneal metastatic spread of human ovarian cancer.
Collapse
Affiliation(s)
- Erica Torchiaro
- Department of Oncology, University of Torino School of Medicine, Turin, Italy.,Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy
| | - Annalisa Lorenzato
- Department of Oncology, University of Torino School of Medicine, Turin, Italy.,Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy
| | - Martina Olivero
- Department of Oncology, University of Torino School of Medicine, Turin, Italy.,Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy
| | - Donatella Valdembri
- Department of Oncology, University of Torino School of Medicine, Turin, Italy.,Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy
| | - Paolo Armando Gagliardi
- Department of Oncology, University of Torino School of Medicine, Turin, Italy.,Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy
| | - Marta Gai
- Department of Molecular Biotechnologies and Health Sciences, University of Turin at the Molecular Biotechnology Center, Torino, Italy
| | - Jessica Erriquez
- Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy
| | - Guido Serini
- Department of Oncology, University of Torino School of Medicine, Turin, Italy.,Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy
| | - Maria Flavia Di Renzo
- Department of Oncology, University of Torino School of Medicine, Turin, Italy.,Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy
| |
Collapse
|
10
|
Musiani D, Konda JD, Pavan S, Torchiaro E, Sassi F, Noghero A, Erriquez J, Perera T, Olivero M, Di Renzo MF. Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy. FASEB J 2014; 28:4055-67. [PMID: 24903273 DOI: 10.1096/fj.13-247924] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2014] [Accepted: 05/27/2014] [Indexed: 12/24/2022]
Abstract
The tyrosine kinase encoded by the MET oncogene is activated by gene mutation or amplification in tumors, which in most instances maintain addiction, i.e., dependency, to MET activation. This makes MET an attractive candidate for targeted therapies. Here we show that, in 3/3 MET-addicted human gastric cancer cell lines, MET kinase inhibition resulted in a 3- to 4-fold increased expression of the antiapoptotic small heat-shock protein of 27 kDa (HSP27, HSPB1). HSP27 increase depended on the inhibition of the MEK/ERK pathway and on heat-shock factor 1 (HSF1) and hypoxia-inducible factor-1α (HIF-1α) regulation. Importantly, HSP27-silenced MET-addicted cells underwent 2- and 3-fold more apoptosis following MET inhibition in vitro and in vivo, respectively. Likewise, in human cancer cells susceptible to epidermal growth factor receptor (EGFR) inhibition, EGFR inhibitors induced HSP27 expression and were strengthened by HSP27 suppression. In control cell lines that were not affected by drugs targeting MET or EGFR, these drugs did not induce HSP27 increase. Therefore, in cancer therapies targeting the MET pathway, the induction of HSP27 might limit the efficacy of anti-MET agents. As HSP27 increase also impairs the effectiveness of EGFR inhibitors and is known to protect cells from chemotherapeutics, the induction of HSP27 by targeted agents might strongly affect the success of combination treatments.
Collapse
Affiliation(s)
- Daniele Musiani
- Department of Oncology, University of Torino School of Medicine, Turin, Italy; Laboratory of Cancer Genetics
| | - John David Konda
- Department of Oncology, University of Torino School of Medicine, Turin, Italy; Laboratory of Cancer Genetics
| | - Simona Pavan
- Department of Oncology, University of Torino School of Medicine, Turin, Italy; Laboratory of Cancer Genetics
| | - Erica Torchiaro
- Department of Oncology, University of Torino School of Medicine, Turin, Italy; Laboratory of Cancer Genetics
| | | | - Alessio Noghero
- Department of Oncology, University of Torino School of Medicine, Turin, Italy; Laboratory of Vascular Oncology, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy; and
| | | | | | - Martina Olivero
- Department of Oncology, University of Torino School of Medicine, Turin, Italy; Laboratory of Cancer Genetics
| | - Maria Flavia Di Renzo
- Department of Oncology, University of Torino School of Medicine, Turin, Italy; Laboratory of Cancer Genetics
| |
Collapse
|
11
|
Pavan S, Musiani D, Torchiaro E, Migliardi G, Erriquez J, Olivero M, Renzo MFD. Abstract B3: HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor. Clin Cancer Res 2013. [DOI: 10.1158/1078-0432.ovca13-b3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The Hepatocyte Growth Factor (HGF) also known as Scatter Factor, activates cancer cell invasion and metastasis. We show that in ovarian cancer cells HGF induced the phosphorylation of the small heat shock protein of 27KDa (HSP27) by activating the p38MAPK. HSP27 is increased in many cancers at advanced stage including ovarian cancer and associated with cancer resistance to therapy and poor patients' survival. The phosphorylation of HSP27 regulates both its chaperone activity and its control of cytoskeletal stability. We show that HSP27 was necessary for the motility in vitro and the remodeling of actin filaments induced by HGF. In vivo, HSP27 silencing impaired the ability of the highly metastatic, HGF-secreting ovarian cancer cells to give rise to spontaneous metastases. This was due to defective motility across the vessel wall and reduced growth. Indeed, HSP27 silencing impaired both the ability of ovarian cancer cells to form experimental haematogenous metastases and to grow as subcutaneous xenografts. Moreover, HSP27 suppression resulted in the sensitization of xenografts to low doses of the chemotherapeutic Paclitaxel, likely because HSP27 protected microtubules from bundling caused by the drug. Altogether, these data show that the HSP27 is required for the pro-invasive and pro-metastatic activity of HGF and suggest that HSP27 might be not only a marker of progression of ovarian cancer, but also a suitable target for therapy. Grant sponsors: This work has been supported by grants to M.F.D.: 2012 IG grant and 2010 Special Program Molecular Clinical Oncology 5xMille of the Italian Association of Cancer Research (AIRC), Project n° 9970, and Grant of the CARIPLO Foundation.
Citation Format: Simona Pavan, Daniele Musiani, Erica Torchiaro, Giorgia Migliardi, Jessica Erriquez, Martina Olivero, Maria Flavia Di Renzo. HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic; Sep 18-21, 2013; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2013;19(19 Suppl):Abstract nr B3.
Collapse
|
12
|
Pavan S, Musiani D, Torchiaro E, Migliardi G, Gai M, Di Cunto F, Erriquez J, Olivero M, Di Renzo MF. HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor. Int J Cancer 2013; 134:1289-99. [DOI: 10.1002/ijc.28464] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2013] [Revised: 07/29/2013] [Accepted: 08/14/2013] [Indexed: 01/10/2023]
Affiliation(s)
- Simona Pavan
- Department of Oncology; University of Torino, School of Medicine; Torino Italy
- Laboratory of Cancer Genetics; Institute for Cancer Research at; Candiolo Torino Italy
| | - Daniele Musiani
- Department of Oncology; University of Torino, School of Medicine; Torino Italy
- Laboratory of Cancer Genetics; Institute for Cancer Research at; Candiolo Torino Italy
| | - Erica Torchiaro
- Department of Oncology; University of Torino, School of Medicine; Torino Italy
- Laboratory of Cancer Genetics; Institute for Cancer Research at; Candiolo Torino Italy
| | - Giorgia Migliardi
- Department of Oncology; University of Torino, School of Medicine; Torino Italy
- Laboratory of Molecular Pharmacology; Institute for Cancer Research at; Candiolo Torino Italy
| | - Marta Gai
- Department of Molecular Biotechnology and Health Sciences Molecular Biotechnology Center; University of Torino; Torino Italy
| | - Ferdinando Di Cunto
- Department of Molecular Biotechnology and Health Sciences Molecular Biotechnology Center; University of Torino; Torino Italy
| | - Jessica Erriquez
- Laboratory of Cancer Genetics; Institute for Cancer Research at; Candiolo Torino Italy
| | - Martina Olivero
- Department of Oncology; University of Torino, School of Medicine; Torino Italy
- Laboratory of Cancer Genetics; Institute for Cancer Research at; Candiolo Torino Italy
| | - Maria Flavia Di Renzo
- Department of Oncology; University of Torino, School of Medicine; Torino Italy
- Laboratory of Cancer Genetics; Institute for Cancer Research at; Candiolo Torino Italy
| |
Collapse
|
13
|
Pignochino Y, Dell'Aglio C, Basiricò M, Capozzi F, Soster M, Marchiò S, Bruno S, Gammaitoni L, Sangiolo D, Torchiaro E, D'Ambrosio L, Fagioli F, Ferrari S, Alberghini M, Picci P, Aglietta M, Grignani G. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res 2013; 19:2117-31. [PMID: 23434734 DOI: 10.1158/1078-0432.ccr-12-2293] [Citation(s) in RCA: 81] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE The multikinase inhibitor sorafenib displays antitumor activity in preclinical models of osteosarcoma. However, in sorafenib-treated patients with metastatic-relapsed osteosarcoma, disease stabilization and tumor shrinkage were short-lived and drug resistance occurred. We explored the sorafenib treatment escape mechanisms to overcome their drawbacks. EXPERIMENTAL DESIGN Immunoprecipitation, Western blotting, and immunohistochemistry were used to analyze the mTOR pathway [mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2)]. Cell viability, colony growth, and cell migration were evaluated in different osteosarcoma cell lines (MNNG-HOS, HOS, KHOS/NP, MG63, U-2OS, SJSA-1, and SAOS-2) after scalar dose treatment with sorafenib (10-0.625 μmol/L), rapamycin-analog everolimus (100-6.25 nmol/L), and combinations of the two. Cell cycle, reactive oxygen species (ROS) production, and apoptosis were assessed by flow cytometry. Nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice injected with MNNG-HOS cells were used to determine antitumor and antimetastatic effects. Angiogenesis and vascularization were evaluated in vitro by exploiting endothelial branching morphogenesis assays and in vivo in xenografted mice and chorioallantoic membranes. RESULTS After sorafenib treatment, mTORC1 signaling was reduced (downstream target P-S6), whereas mTORC2 was increased (phospho-mTOR Ser2481) in MNNG-HOS xenografts compared with vehicle-treated mice. Combining sorafenib with everolimus resulted in complete abrogation of both mTORC1 [through ROS-mediated AMP-activated kinase (AMPK) activation] and mTORC2 (through complex disassembly). The sorafenib/everolimus combination yielded: (i) enhanced antiproliferative and proapoptotic effects, (ii) impaired tumor growth, (iii) potentiated antiangiogenesis, and (iv) reduced migratory and metastatic potential. CONCLUSION mTORC2 activation is an escape mechanism from sorafenib treatment. When sorafenib is combined with everolimus, its antitumor activity is increased by complete inhibition of the mTOR pathway in the preclinical setting.
Collapse
Affiliation(s)
- Ymera Pignochino
- Sarcoma Group, Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment at Candiolo, Torino, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Torchiaro E, Olivero M, Pavan S, Di renzo M. 335 Inhibition of P90RSK Sensitizes Ovarian Cancer Cells to Apoptosis. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71025-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
15
|
Pavan S, Musiani D, Torchiaro E, Migliardi G, Olivero M, Di Renzo M. 254 HSP27 is Involved in Ovarian Cancer Cell Motility and Response to Paclitaxel. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70949-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Musiani D, Rivera AR, Konda JD, Pavan S, Torchiaro E, Olivero M, Di Renzo MF. Abstract B42: Heat Shock Protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibition and limits the effectiveness of inhibitors. Clin Cancer Res 2012. [DOI: 10.1158/1078-0432.mechres-b42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The receptor for the hepatocyte growth factor (HGF) is encoded by the MET oncogene and its activation results in cell growth, survival, motility and invasiveness. Deregulated HGF/MET signaling is observed in many tumors and both HGF and MET are attractive candidates for targeted therapies. Unexpectedly, we found that in ovarian cancer cells the activation of the MET receptor downmodulated the expression of the small heat shock protein 27 (HSP27), which functions as a molecular chaperone and as an antiapoptotic protein. In MET addicted gastric carcinoma cells, where MET is constitutively active, MET kinase inhibition by JNJ-38877605 up-regulated HSP27 expression. More importantly, in these gastric carcinoma cells suppression of HSP27 was alone able to induce cell death and increased cell susceptibility to MET inhibition. HSP27 suppression did not affect MET stability and phosphorylation, but increased activation of caspase 3, which is a known HSP27 client protein. Regulation of HSP27 expression by MET signaling occurred at transcriptional level, as confirmed by the use of HSP27 promoter in a reporter assay. It was not due to the engagement of HSF1, the master key transcription factor regulating HSPs expression, but depended on MEK activation and resulting HIF 1alpha stabilization. MEK inhibition and HIF 1 alpha silencing resulted in the induction of HSP27, suggesting a direct or indirect transcriptional repression. Altogether data show that MET activation down-regulates and MET inhibition up-regulates HSP27 expression, and that HSP27 increased expression protects cells from death induced by MET inhibitors. Therefore, in therapies with MET targeting agents, HSP27 increase might impair the effectiveness of MET inhibitors. As it is known that HSP27 protects cells for chemotherapeutics, data suggest that HSP27 might strongly affect combinatorial treatments.
Collapse
Affiliation(s)
- Daniele Musiani
- 1Institute for Cancer Research and Treatment, IRCC, Turin, Italy, 2Instituto de Biopatología y Medicina Regenerativa (IBIMER), Granada, Spain
| | - Alberto Ramirez Rivera
- 1Institute for Cancer Research and Treatment, IRCC, Turin, Italy, 2Instituto de Biopatología y Medicina Regenerativa (IBIMER), Granada, Spain
| | - John David Konda
- 1Institute for Cancer Research and Treatment, IRCC, Turin, Italy, 2Instituto de Biopatología y Medicina Regenerativa (IBIMER), Granada, Spain
| | - Simona Pavan
- 1Institute for Cancer Research and Treatment, IRCC, Turin, Italy, 2Instituto de Biopatología y Medicina Regenerativa (IBIMER), Granada, Spain
| | - Erica Torchiaro
- 1Institute for Cancer Research and Treatment, IRCC, Turin, Italy, 2Instituto de Biopatología y Medicina Regenerativa (IBIMER), Granada, Spain
| | - Martina Olivero
- 1Institute for Cancer Research and Treatment, IRCC, Turin, Italy, 2Instituto de Biopatología y Medicina Regenerativa (IBIMER), Granada, Spain
| | - Maria Flavia Di Renzo
- 1Institute for Cancer Research and Treatment, IRCC, Turin, Italy, 2Instituto de Biopatología y Medicina Regenerativa (IBIMER), Granada, Spain
| |
Collapse
|